Please login to the form below

Not currently logged in
Email:
Password:

Pharma urged to tackle non-compliance

The pharma industry must act to combat patient non-compliance, which averages at 50 per cent for long-term conditions, such as HIV and arthritis, according to a Capgemini report

The pharma industry must act to combat patient non-compliance, which averages at 50 per cent for long-term conditions, such as HIV and arthritis, according to a Capgemini report.

The report estimates that patient non-adherence to prescribed medicine courses is responsible for 194,500 deaths per year in the EU and 131,400 deaths per year in the US. Nonadherence results in annual costs of close to €125bn in the EU and $300bn in the US.

Jean-Marc Neimetz, global leader of the life sciences practice Capgemini Consulting, said: "The pharmaceutical industry needs to address patient adherence in a more strategic and integrated part of its activities, which will be good for the patients and for the industry overall."

They need to design and deploy programmes targeted to the very specific patient situations and leverage both traditional and digital approaches to do so, added Thomas Forissier, a principal of the life sciences practice at Capgemini Consulting.

The report said that almost all chronic conditions face high rates of non-adherence and those with no visible symptoms, such as depression, have the lowest adherence rates. The problem even extends to oral formulation chemotherapy drugs, where there is less expectation to counter patient adherence issues due to the seriousness of the condition. As much as 40 per cent of cancer patients are non-adherent in this case.

2nd June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics